Mankind Pharma

Market Cap: Large Cap
Industry: Pharmaceuticals & Biotechnology
ISIN: INE634S01028
NSEID: MANKIND
BSEID: 543904

INR

2,174.00

30.9 (1.44%)

BSENSE

Dec 19

BSE+NSE Vol: 5.01 lacs

{
  "main_header": {
    "sid": 1003845,
    "name": "Mankind Pharma",
    "stock_name": "Mankind Pharma",
    "full_name": "Mankind Pharma Ltd",
    "name_url": "stocks-analysis/mankind-pharma",
    "exchange": 0,
    "exchangecode": "",
    "country_id": 34,
    "currency": "INR",
    "cmp": "2,174.00",
    "chg": 30.9,
    "chgp": "1.44%",
    "dir": 1,
    "prev_price": "2,143.10",
    "mcapval": "89,166.00 Cr",
    "mcap": "Large Cap",
    "scripcode": 543904,
    "symbol": "MANKIND",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "indexname": "",
    "isin": "INE634S01028",
    "curr_date": "Dec 19",
    "curr_time": "",
    "bse_nse_vol": "5.01 lacs",
    "exc_status": "Active",
    "traded_date": "Dec 19, 2025",
    "traded_date_str": "2025 12 19",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/mankind-pharma-1003845-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Mankind Pharma Stock Falls to 52-Week Low of Rs.2100.1 Amidst Sector Pressure",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/mankind-pharma-stock-falls-to-52-week-low-of-rs21001-amidst-underperformance-3760996",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/MankindPharma_priceRelatedfactors_3760996.png",
        "date": "2025-12-17 09:56:01",
        "description": "Mankind Pharma's shares reached a new 52-week low of Rs.2100.1 today, marking a significant price level for the pharmaceutical company as it continues to trade below key moving averages amid broader market fluctuations."
      },
      {
        "title": "Why is Mankind Pharma falling/rising?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/why-is-mankind-pharma-fallingrising-3760566",
        "imagepath": "",
        "date": "2025-12-17 01:17:23",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n\n<p><strong>Recent Price Movement and Market Performance</strong></p>\n<p>The stock has been under pressure for the past week, registering a 3.34% loss while the Sensex remained virtually flat with a marginal 0.02% gain. Over the past month, Mankind Pharma’s shares have declined by 7.08%, contrasting with a slight 0.14% rise in the benchmark index. Year-to-date, the stock has plunged 26.78%, significantly underperforming the Sensex’s 8.37% gain. This underperformance extends to the one-year horizon, where the stock has lost 21.63% against the Sensex’s 3.59% appreciation.</p>\n<p>On 16-Dec, the stock hit a new 52-week low of ₹2,103.05, underscoring the persistent selling pressure. It has also underperformed its sector by 1.17% on the day and has been declining for two consecutive sessions, losing 3.36% in ..."
      },
      {
        "title": "Mankind Pharma Stock Falls to 52-Week Low of Rs.2103.05 Amidst Market Pressure",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/mankind-pharma-stock-falls-to-52-week-low-of-rs210305-on-16-dec-2025-3760207",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/MankindPharma_priceRelatedfactors_3760207.png",
        "date": "2025-12-16 14:47:54",
        "description": "Mankind Pharma’s shares touched a fresh 52-week low of Rs.2103.05 today, marking a significant decline amid broader market volatility and sector underperformance. The stock has been trading below all key moving averages, reflecting sustained downward momentum over recent sessions."
      },
      {
        "title": "Mankind Pharma Faces Sharp Correction Amidst Underwhelming Performance",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/mankind-pharma-shares-plunge-over-30-from-peak-amid-valuation-concerns-and-earnings-pressure-3760164",
        "imagepath": "",
        "date": "2025-12-16 13:09:03",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n                <p><strong>Performance Overview and Market Context</strong></p>\n                <p>Over the past year, Mankind Pharma’s stock has recorded a return of -21.08%, while the Sensex benchmark has shown a positive performance of 3.66%. This divergence highlights the stock’s underperformance relative to the broader market. The trend extends across multiple time frames: a one-month decline of 6.43% against a Sensex gain of 0.21%, and a three-month drop of 17.40% compared to the Sensex’s 2.87% rise. Year-to-date figures further underline this disparity, with Mankind Pharma down 26.27% versus the Sensex’s 8.45% increase.</p>\n                <p>Longer-term data reveals a more pronounced gap. Over three and five years, Mankind Pharma’s stock has remained flat, while the Sensex has advanced by 38.16%..."
      },
      {
        "title": "Mankind Pharma Sees Revision in Market Assessment Amidst Valuation and Performance Challenges",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/mankind-pharma-downgraded-to-sell-by-marketsmojo-amidst-weak-financial-and-technical-trends-3756184",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/MankindPharma_mojoScore_3756184.png",
        "date": "2025-12-11 10:10:16",
        "description": "Mankind Pharma's market evaluation has undergone a notable revision, reflecting shifts in its financial and technical outlook. The pharmaceutical company’s recent assessment highlights a complex interplay of valuation concerns, flat financial trends, and subdued technical indicators, set against a backdrop of underwhelming stock returns over the past year."
      },
      {
        "title": "Mankind Pharma Sees Notable Surge in Derivatives Open Interest Amid Market Volatility",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/mankind-pharma-sees-sharp-open-interest-rise-amid-weak-price-momentum-3744453",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/MankindPharma_oi_spurts_by_underlying_3744453.png",
        "date": "2025-12-03 15:00:12",
        "description": "Mankind Pharma has experienced a significant rise in open interest in its derivatives segment, signalling a shift in market positioning amid recent price movements and sector trends. This development comes as the stock trades close to its 52-week low, with volume and futures activity reflecting evolving investor sentiment in the Pharmaceuticals & Biotechnology sector."
      },
      {
        "title": "Is Mankind Pharma technically bullish or bearish?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-mankind-pharma-technically-bullish-or-bearish-3740546",
        "imagepath": "",
        "date": "2025-12-02 09:14:18",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n\n<p><strong>Overview of Current Price Action and Trend</strong></p>\n<p>Mankind Pharma’s share price currently stands at ₹2,235.40, slightly down from the previous close of ₹2,251.85. The stock has traded within a daily range of ₹2,224.70 to ₹2,271.95, reflecting modest intraday volatility. Over the past 52 weeks, the stock has seen a high of ₹3,050.00 and a low of ₹2,115.50, indicating a significant drawdown from its peak levels.</p>\n<p>The technical trend’s recent shift from mildly bearish to bearish signals a deterioration in momentum, suggesting that sellers are gaining control. This change is critical for traders and investors who rely on technical analysis to time their entries and exits.</p>\n<p><strong>Technical Indicators: Mixed but Leaning Bearish</strong></p>\n<p>Examining the key technical indi..."
      },
      {
        "title": "Mankind Pharma Technical Momentum Shifts Amid Market Challenges",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/mankind-pharma-technical-momentum-shifts-amid-bearish-signals-3740452",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/MankindPharma_technicaldot_3740452.png",
        "date": "2025-12-02 08:12:59",
        "description": "Mankind Pharma's recent technical indicators reveal a shift in price momentum, reflecting evolving market dynamics within the Pharmaceuticals & Biotechnology sector. The stock's performance, combined with key technical signals such as MACD, RSI, and moving averages, provides a nuanced picture of its current market stance amid broader index trends."
      },
      {
        "title": "Mankind Pharma Sees Notable Surge in Derivatives Open Interest Amid Market Volatility",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/mankind-pharma-sees-sharp-open-interest-rise-amid-weak-price-action-3738854",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/MankindPharma_oi_spurts_by_underlying_3738854.png",
        "date": "2025-12-01 15:00:10",
        "description": "Mankind Pharma has experienced a significant rise in open interest within its derivatives segment, signalling heightened market activity and evolving investor positioning. This development comes amid subdued price movement and a broader market environment marked by cautious sentiment in the Pharmaceuticals & Biotechnology sector."
      }
    ],
    "total": 427,
    "sid": "1003845",
    "stock_news_url": "https://www.marketsmojo.com/news/mankind-pharma-1003845"
  },
  "announcements": [
    {
      "caption": "Intimation Regarding ESG Rating",
      "datetime": "10-Dec-2025",
      "details": "Please find attached intimation regard ESG rating",
      "source": "BSE"
    },
    {
      "caption": "Intimation Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 (Listing Regulations)",
      "datetime": "10-Dec-2025",
      "details": "Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 (Listing Regulations)",
      "source": "BSE"
    },
    {
      "caption": "Intimation Regarding ESG Rating",
      "datetime": "28-Nov-2025",
      "details": "Please find attached intimation regarding ESG Rating assigned by SES ESG Research Private Limited.",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "",
      "data": [
        {
          "txt": "Mankind Pharma Ltd has declared <strong>100%</strong> dividend, ex-date: 08 Aug 25",
          "dt": "2025-08-08",
          "middle_text": "Dividend Alert"
        }
      ]
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Mankind Pharma Stock Falls to 52-Week Low of Rs.2100.1 Amidst Sector Pressure

2025-12-17 09:56:01

Mankind Pharma's shares reached a new 52-week low of Rs.2100.1 today, marking a significant price level for the pharmaceutical company as it continues to trade below key moving averages amid broader market fluctuations.

Why is Mankind Pharma falling/rising?

2025-12-17 01:17:23

Recent Price Movement and Market Performance

The stock has been under pressure for the past week, registering a 3.34% loss while the Sensex remained virtually flat with a marginal 0.02% gain. Over the past month, Mankind Pharma’s shares have declined by 7.08%, contrasting with a slight 0.14% rise in the benchmark index. Year-to-date, the stock has plunged 26.78%, significantly underperforming the Sensex’s 8.37% gain. This underperformance extends to the one-year horizon, where the stock has lost 21.63% against the Sensex’s 3.59% appreciation.

On 16-Dec, the stock hit a new 52-week low of ₹2,103.05, underscoring the persistent selling pressure. It has also underperformed its sector by 1.17% on the day and has been declining for two consecutive sessions, losing 3.36% in ...

Mankind Pharma Stock Falls to 52-Week Low of Rs.2103.05 Amidst Market Pressure

2025-12-16 14:47:54

Mankind Pharma’s shares touched a fresh 52-week low of Rs.2103.05 today, marking a significant decline amid broader market volatility and sector underperformance. The stock has been trading below all key moving averages, reflecting sustained downward momentum over recent sessions.

Mankind Pharma Faces Sharp Correction Amidst Underwhelming Performance

2025-12-16 13:09:03

Performance Overview and Market Context

Over the past year, Mankind Pharma’s stock has recorded a return of -21.08%, while the Sensex benchmark has shown a positive performance of 3.66%. This divergence highlights the stock’s underperformance relative to the broader market. The trend extends across multiple time frames: a one-month decline of 6.43% against a Sensex gain of 0.21%, and a three-month drop of 17.40% compared to the Sensex’s 2.87% rise. Year-to-date figures further underline this disparity, with Mankind Pharma down 26.27% versus the Sensex’s 8.45% increase.

Longer-term data reveals a more pronounced gap. Over three and five years, Mankind Pharma’s stock has remained flat, while the Sensex has advanced by 38.16%...

Mankind Pharma Sees Revision in Market Assessment Amidst Valuation and Performance Challenges

2025-12-11 10:10:16

Mankind Pharma's market evaluation has undergone a notable revision, reflecting shifts in its financial and technical outlook. The pharmaceutical company’s recent assessment highlights a complex interplay of valuation concerns, flat financial trends, and subdued technical indicators, set against a backdrop of underwhelming stock returns over the past year.

Mankind Pharma Sees Notable Surge in Derivatives Open Interest Amid Market Volatility

2025-12-03 15:00:12

Mankind Pharma has experienced a significant rise in open interest in its derivatives segment, signalling a shift in market positioning amid recent price movements and sector trends. This development comes as the stock trades close to its 52-week low, with volume and futures activity reflecting evolving investor sentiment in the Pharmaceuticals & Biotechnology sector.

Is Mankind Pharma technically bullish or bearish?

2025-12-02 09:14:18

Overview of Current Price Action and Trend

Mankind Pharma’s share price currently stands at ₹2,235.40, slightly down from the previous close of ₹2,251.85. The stock has traded within a daily range of ₹2,224.70 to ₹2,271.95, reflecting modest intraday volatility. Over the past 52 weeks, the stock has seen a high of ₹3,050.00 and a low of ₹2,115.50, indicating a significant drawdown from its peak levels.

The technical trend’s recent shift from mildly bearish to bearish signals a deterioration in momentum, suggesting that sellers are gaining control. This change is critical for traders and investors who rely on technical analysis to time their entries and exits.

Technical Indicators: Mixed but Leaning Bearish

Examining the key technical indi...

Mankind Pharma Technical Momentum Shifts Amid Market Challenges

2025-12-02 08:12:59

Mankind Pharma's recent technical indicators reveal a shift in price momentum, reflecting evolving market dynamics within the Pharmaceuticals & Biotechnology sector. The stock's performance, combined with key technical signals such as MACD, RSI, and moving averages, provides a nuanced picture of its current market stance amid broader index trends.

Mankind Pharma Sees Notable Surge in Derivatives Open Interest Amid Market Volatility

2025-12-01 15:00:10

Mankind Pharma has experienced a significant rise in open interest within its derivatives segment, signalling heightened market activity and evolving investor positioning. This development comes amid subdued price movement and a broader market environment marked by cautious sentiment in the Pharmaceuticals & Biotechnology sector.